Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medicofarma BiotechWAR:MDB 34 Receivables Turnover is 0.11 as of Mar. 2026. GuruFocus rates WAR:MDB with a GF Score™ of 34/100 and a GF Value™ of zł0.05 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 950 Drug Manufacturers companies, Medicofarma Biotech ranks worse than 99.58% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Medicofarma Biotech's Revenue for the
three
months ended in Mar. 2026 was zł0.04 Mil. Medicofarma Biotech's average Accounts Receivable for the
three
months ended in Mar. 2026 was zł0.32 Mil.
Hence, Medicofarma Biotech's Receivables Turnover for the
three
months ended in Mar. 2026 was 0.11.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Medicofarma Biotech Receivables Turnover Related Terms
Medicofarma Biotech Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Medicofarma Biotech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:MDB vs ZTS, UTHR, VTRS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medicofarma Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicofarma Biotech Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicofarma Biotech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Medicofarma Biotech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medicofarma Biotech (WAR:MDB) has a Receivables Turnover of 0.11 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Medicofarma Biotech and its competitors. According to the industry distribution chart, Medicofarma Biotech ranks #946 out of 950 companies in the Drug Manufacturers industry, placing it in the top 99.6%.
Is Medicofarma Biotech's Receivables Turnover too high?
Medicofarma Biotech's current Receivables Turnover is 0.11. The Drug Manufacturers industry median Receivables Turnover is 5.07. Medicofarma Biotech's value of 0.11 is 97.8% below this industry median. Based on the distribution chart, Medicofarma Biotech ranks #946 out of 950 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicofarma Biotech has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medicofarma Biotech's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Medicofarma Biotech ranks #946 out of 950 companies for Receivables Turnover. This places Medicofarma Biotech in the lower half of its industry. The industry median Receivables Turnover is 5.07. Medicofarma Biotech's value of 0.11 is 97.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medicofarma Biotech's current Receivables Turnover of 0.11 is 97.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Medicofarma Biotech and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicofarma Biotech's current Receivables Turnover is 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicofarma Biotech stock overvalued right now?
Based on GuruFocus' analysis, Medicofarma Biotech (WAR:MDB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł0.05, compared to a current price of zł0.41 — trading 724% above its estimated fair value. The current Receivables Turnover is 0.11 and 97.8% below the Drug Manufacturers industry median of 5.07. Medicofarma Biotech's overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Medicofarma Biotech (WAR:MDB), the current Receivables Turnover is 0.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicofarma Biotech (WAR:MDB) Overvalued in 2026?
Based on GuruFocus' analysis, Medicofarma Biotech stock appears to be overvalued.
The current stock price of zł0.41 is trading 724% above its estimated GF Value™ of zł0.05.
GuruFocus considers Medicofarma Biotech to be Significantly Overvalued.
Key valuation signals for WAR:MDB:
Receivables Turnover: 0.11
GF Value™: zł0.05 vs. price of zł0.41 (724% above fair value)
Industry Position: 97.8% below the Drug Manufacturers median (#946 of 950)
No single metric tells the full story. See the WAR:MDB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicofarma Biotech SA operates in the pharmaceutical industry. The company specializes in contract manufacturing of medical devices, medicinal products and dietary supplements. The business is spread across Austria, Czech Republic, Spain, Ireland, Canada, Germany, Norway, Sweden, Great Britain, and Italy.
34GF Score
Get the complete analysis for WAR:MDB
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:MDB has been successfully added to your 
